Literature DB >> 27052664

Rapid Restoration of Thrombus Formation and High-Molecular-Weight von Willebrand Factor Multimers in Patients with Severe Aortic Stenosis After Valve Replacement.

Keigo Yamashita1, Hideo Yagi, Masaki Hayakawa, Takehisa Abe, Yoshihiro Hayata, Naoko Yamaguchi, Mitsuhiko Sugimoto, Yoshihiro Fujimura, Masanori Matsumoto, Shigeki Taniguchi.   

Abstract

AIM: Patients with severe aortic stenosis (AS) may have bleeding episodes due to the loss of high-molecular-weight (HMW) von Willebrand factor multimers (VWFMs). The absence of HMW-VWFMs and bleeding tendency are usually corrected after aortic valve replacement (AVR). To investigate the process of VWFM recovery and symptoms in patients with severe AS, we analyzed changes in VWF antigen (VWF:Ag), ADAMTS13 activity (ADAMTS13:AC), and platelet thrombus formation under high shear stress conditions.
METHODS: Nine patients with severe AS undergoing AVR were analyzed.
RESULTS: Evident deficiency of HMW-VWFMs was observed in six patients before surgery, which was rapidly restored within 8 days after AVR. Median levels of VWF:Ag before surgery, on postoperative days (PODs) 1, 8, 15, and 22, and one year after AVR were 78.1%, 130%, 224%, 155%, 134%, and 142%, respectively. In contrast, ADAMTS13:AC was 50.5%, 35.5%, 25.5%, 25.1%, 30.3%, and 84.6%, respectively. Preoperative thrombus formation but not surface coverage was significantly lower than that on POD 22, which was considered as normal level in each patient. Compared with preoperative levels, thrombus volume was significantly lower on POD 1, but rapidly increased by POD 8.
CONCLUSION: Bleeding tendency and loss of HMW-VWFMs observed in patients with severe AS before surgery was rapidly corrected after AVR. Instead, patients were in a VWF-predominant state between POD 8 and 22.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27052664      PMCID: PMC5098915          DOI: 10.5551/jat.34421

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  29 in total

1.  Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice.

Authors:  Helmut Baumgartner; Judy Hung; Javier Bermejo; John B Chambers; Arturo Evangelista; Brian P Griffin; Bernard Iung; Catherine M Otto; Patricia A Pellikka; Miguel Quiñones
Journal:  J Am Soc Echocardiogr       Date:  2009-01       Impact factor: 5.251

2.  Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.

Authors:  Seiji Kato; Masanori Matsumoto; Tomomi Matsuyama; Ayami Isonishi; Hisahide Hiura; Yoshihiro Fujimura
Journal:  Transfusion       Date:  2006-08       Impact factor: 3.157

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

4.  Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy.

Authors:  Johannes Kalbhenn; Rene Schmidt; Lea Nakamura; Johannes Schelling; Simone Rosenfelder; Barbara Zieger
Journal:  J Atheroscler Thromb       Date:  2014-09-04       Impact factor: 4.928

5.  Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes.

Authors:  U Budde; R Schneppenheim; H Plendl; J Dent; Z M Ruggeri; T S Zimmerman
Journal:  Thromb Haemost       Date:  1990-04-12       Impact factor: 5.249

6.  Acquired von Willebrand syndrome in aortic stenosis.

Authors:  André Vincentelli; Sophie Susen; Thierry Le Tourneau; Isabelle Six; Olivier Fabre; Francis Juthier; Anne Bauters; Christophe Decoene; Jenny Goudemand; Alain Prat; Brigitte Jude
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

7.  An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome.

Authors:  Greg C G Hugenholtz; Jelle Adelmeijer; Joost C M Meijers; Robert J Porte; R Todd Stravitz; Ton Lisman
Journal:  Hepatology       Date:  2013-07-01       Impact factor: 17.425

8.  Distinct and concerted functions of von Willebrand factor and fibrinogen in mural thrombus growth under high shear flow.

Authors:  Hideto Matsui; Mitsuhiko Sugimoto; Tomohiro Mizuno; Shizuko Tsuji; Shigeki Miyata; Michio Matsuda; Akira Yoshioka
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

9.  Prediction of Molecular Interaction between Platelet Glycoprotein Ibα and von Willebrand Factor using Molecular Dynamics Simulations.

Authors:  Seiji Shiozaki; Shu Takagi; Shinya Goto
Journal:  J Atheroscler Thromb       Date:  2015-11-17       Impact factor: 4.928

10.  Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels.

Authors:  M Matsumoto; K Kawa; M Uemura; S Kato; H Ishizashi; A Isonishi; H Yagi; Y-D Park; Y Takeshima; Y Kosaka; H Hara; S Kai; A Kanamaru; S Fukuhara; M Hino; M Sako; A Hiraoka; H Ogawa; J Hara; Y Fujimura
Journal:  Bone Marrow Transplant       Date:  2007-06-04       Impact factor: 5.483

View more
  8 in total

1.  Turbulent Flow Promotes Cleavage of VWF (von Willebrand Factor) by ADAMTS13 (A Disintegrin and Metalloproteinase With a Thrombospondin Type-1 Motif, Member 13).

Authors:  Maria Bortot; Katrina Ashworth; Alireza Sharifi; Faye Walker; Nathan C Crawford; Keith B Neeves; David Bark; Jorge Di Paola
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-11       Impact factor: 10.514

2.  Subsequent Response of VWF and ADAMTS13 to Aortic Valve Replacement.

Authors:  Koichi Kokame
Journal:  J Atheroscler Thromb       Date:  2016-07-29       Impact factor: 4.928

3.  Pre-procedural abnormal function of von Willebrand Factor is predictive of bleeding after surgical but not transcatheter aortic valve replacement.

Authors:  Kajetan Grodecki; Karol Zbroński; Elżbieta Przybyszewska-Kazulak; Anna Olasińska-Wiśniewska; Radosław Wilimski; Bartosz Rymuza; Piotr Scisło; Paweł Czub; Dominika Koper; Janusz Kochman; Katarzyna Pawlak; Olga Ciepiela; Marek Grygier; Marek Jemielity; Maciej Lesiak; Krzysztof J Filipiak; Grzegorz Opolski; Zenon Huczek
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

Review 4.  Platelets: Implications in Aortic Valve Stenosis and Bioprosthetic Valve Dysfunction From Pathophysiology to Clinical Care.

Authors:  Stephanie L Sellers; Gaurav S Gulsin; Devyn Zaminski; Rong Bing; Azeem Latib; Janarthanan Sathananthan; Philippe Pibarot; Rihab Bouchareb
Journal:  JACC Basic Transl Sci       Date:  2021-11-17

Review 5.  MicroRNAs in Valvular Heart Diseases: Potential Role as Markers and Actors of Valvular and Cardiac Remodeling.

Authors:  Cécile Oury; Laurence Servais; Nassim Bouznad; Alexandre Hego; Alain Nchimi; Patrizio Lancellotti
Journal:  Int J Mol Sci       Date:  2016-07-13       Impact factor: 5.923

6.  Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease.

Authors:  Axel Dimberg; Ulrica Alström; Elisabeth Ståhle; Christina Christersson
Journal:  Clin Appl Thromb Hemost       Date:  2018-05-16       Impact factor: 2.389

7.  Disappearance of Angiodysplasia Following Transcatheter Aortic Valve Implantation in a Patient with Heyde's Syndrome: A Case Report and Review of the Literature.

Authors:  Satoshi Tsuchiya; Yasuharu Matsumoto; Tsuyoshi Doman; Taku Fujiya; Jun Sugisawa; Akira Suda; Koichi Sato; Shohei Ikeda; Tomohiko Shindo; Yoku Kikuchi; Kiyotaka Hao; Jun Takahashi; Waku Hatta; Tomoyuki Koike; Atsushi Masamune; Yoshikatsu Saiki; Hisanori Horiuchi; Hiroaki Shimokawa
Journal:  J Atheroscler Thromb       Date:  2019-08-03       Impact factor: 4.928

Review 8.  Leaflet immobility and thrombosis in transcatheter aortic valve replacement.

Authors:  Arnold C T Ng; David R Holmes; Michael J Mack; Victoria Delgado; Raj Makkar; Philipp Blanke; Jonathon A Leipsic; Martin B Leon; Jeroen J Bax
Journal:  Eur Heart J       Date:  2020-09-01       Impact factor: 35.855

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.